Ticagrelor
Platelet Aggregation Inhibitors Excl. Heparin
Sold as Possia · Brilique · BRILINTA
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 164
- FDA reports (12 mo)
- 1,371
Overview
Ticagrelor is an active pharmaceutical ingredient in the Platelet Aggregation Inhibitors Excl. Heparin group (B01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 147 | May 22, 2026 |
| CA Canada | Health Canada | 14 | May 20, 2026 |
| US United States | FDA | 2 | October 28, 2025 |
| EU European Union | EMA | 1 | March 31, 2026 |
GBUnited Kingdom· MHRA
147 products
Uses
1).
How to take
CACanada· Health Canada
14 products
Uses
4 Geriatrics 11/2024 Table of Contents RECENT MAJOR LABEL CHANGES ............................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS ................................................................................................................. 1 Pediatrics ....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................
4 4 DOSAGE AND ADMINISTRATION ................................................................................... 1 Dosing Considerations.................................................................................................
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. 1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.
While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). 2 ) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
1 Acute Coronary Syndrome or a History of Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
EUEuropean Union· EMA
1 product
Uses
1).
How to take
Drug interactions
Known interactions involving Ticagrelor. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 386. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL566970032 · revised July 18, 2025
- [2]Health Canada (DPD) · 02471914 · revised March 22, 2025
- [3]FDA DailyMed · 1225fd45-9b56-16… · revised October 28, 2025 [PDF]
- [4]European Medicines Agency · EMEA/H/C/001241 · revised March 31, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.